Impact of new prognostic markers in treatment decisions in acute myeloid leukemia
- 1 March 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Hematology
- Vol. 16 (2), 98-104
- https://doi.org/10.1097/moh.0b013e3283257adb
Abstract
In recent years, new molecular markers have emerged as significant prognostic parameters and as potential targets for molecularly targeted therapy in acute myeloid leukemia (AML). However, prognostic markers cannot guide the decision for a specific treatment, as they are associated with a differential outcome regardless of the given treatment. In contrast, predictive markers indicate a treatment benefit in patients that are characterized through these markers. Thus, predictive markers can guide clinical decision-making. In young adults, mutations of the nucleophosmin (gene 9NPM1) in the absence of concurrent FLT3-internal tandem duplication (ITD) (FLT3-ITD) have impressive prognostic and, beyond prognostication, predictive properties. This NPM1/FLT3-ITD genotype predicts equivalent favorable outcome after intensive chemotherapy and allogeneic stem cell transplantation, whereas in the absence of this marker clinical outcome was significantly improved after an allogeneic transplantation. In addition, within a retrospective study performed on older adults, the same genotype predicted a significantly improved outcome if all-trans retinoic acid was added to intensive chemotherapy. The discovery of new prognostic and predictive markers has increased our understanding of leukemogenesis and this may lead to improved prognostication and, more important, to novel genotype-specific treatment strategies.Keywords
This publication has 52 references indexed in Scilit:
- Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex KaryotypeJournal of Clinical Oncology, 2008
- Prognostic Implications of Gene Mutations in Acute Myeloid Leukemia With Normal CytogeneticsSeminars in Oncology, 2008
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid LeukemiaThe New England Journal of Medicine, 2008
- Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advancesCurrent Opinion in Hematology, 2007
- Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-BBlood, 2006
- Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment TrialsJournal of Clinical Oncology, 2005
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002
- The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialBlood, 2001
- The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 TrialBlood, 1998
- Statistical aspects of prognostic factor studies in oncologyBritish Journal of Cancer, 1994